by Truveta Research | Aug 22, 2024 | Research, Research Insights
Authors: Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl, PhD ⊕Truveta, Inc, Bellevue, WA, Charlotte Baker, DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc,...
by Truveta staff | Aug 15, 2024 | Research
Psoriasis is more than just a skin condition – it’s a chronic, systemic disease that affects over 8 million people in the United States, profoundly impacting their quality of life. As a complex, immune-mediated disease, psoriasis presents a variety of challenges to...
by Truveta Research | Aug 6, 2024 | Research, Research Insights
Authors: Patricia J. Rodriguez, PhD MPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright ⊕Truveta, Inc, Bellevue, WA, Samuel Gratzl PhD ⊕Truveta, Inc, Bellevue, WA, Charlotte Baker DrPH MPH CPH ⊕Truveta, Inc, Bellevue, WA, Nicholas Stucky, MD PhD ⊕Truveta,...
by Truveta staff | Jul 30, 2024 | Research
By the time most women with ovarian cancer are diagnosed, 70-80% are already at an advanced stage of the disease. Despite declining mortality rates over the past decade, the 5-year survival rate for patients with ovarian cancer remains less than 30%. Sometimes...
by Truveta Research | Jul 30, 2024 | Research
This study characterized discontinuation and reinitiation of GLP-1 medications for a large population of patients with overweight or obesity who started a GLP-1 medication between 2018-2023. The study also identified factors associated with stopping and subsequently...
by Truveta Research | Jul 25, 2024 | Research, Research Insights
The analysis was based on a sample of 17,501,982 patients from January 2018 to May 2024. During the study period, 9,271 patients were tested (using CPT code 93922) for the first time and had a diagnosis of peripheral vascular disease/peripheral artery disease...
